Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
10 hedge funds and large institutions have $387K invested in Rosetta Genomics Ltd. in 2013 Q2 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
7% less call options, than puts
Call options by funds: $100K | Put options by funds: $108K
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OC
1
Oppenheimer & Co
New York
| $153K | +$167K | +3,750 | New |
|
|
KCG
2
Knight Capital Group
| $58K | +$63K | +1,418 | New |
|
3
Millennium Management
New York
| $51K | +$55.9K | +1,258 | New |
|
4
Citadel Advisors
Miami,
Florida
| $49K | +$53.9K | +1,214 | New |
|
5
Group One Trading
Chicago,
Illinois
| $42K | +$45.7K | +1,028 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $15K | +$16.4K | +369 | New |
|
7
Creative Planning
Overland Park,
Kansas
| $8K | +$8.88K | +200 | New |
|
8
Citigroup
New York
| $7K | +$8.09K | +182 | New |
|
|
AIG
9
American International Group
New York
| $4.24K | +$4.62K | +104 | New |
|
10
California Public Employees Retirement System
Sacramento,
California
| – | +$400 | +9 | New |
|
ROSG Hedge Fund Activity: Q2 2013 in Review
10 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q2 2013, worth a combined $387K.
Buyers outnumbered sellers: 10 funds opened new ROSG positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.
- 10 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $387K of Rosetta Genomics Ltd. stock for Q2 2013.
- 10 funds opened new Rosetta Genomics Ltd. positions in Q2 2013 and 0 closed out, a net change of +10 holders.
Based on aggregated 13F filings for Q2 2013.